Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine
2015-003500-23Phase 3
- Sponsor
- Sanofi
- Start
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of acellular pertussis vaccine in Tetanus, diphtheria and pertussis (2 arms), sponsored by Sanofi. Primary endpoint: Seroprotection and booster responses for diphtheria and tetanus.
02
Drugs
acellular pertussis vaccine
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on 2015-003500-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003500-23.